Marco Boorsma PhD
General Partner
Orbis’ platform is the first to systematically explore the macrocycle chemical space using a unique combination of high-throughput chemical synthesis and large-scale assaying, supported by machine learning
Orbis Medicines is a leader in oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties defined by the presence of a cyclic structure.
The company's portfolio of next-generation macrocycle drugs called ‘nCycles’ are systematically designed by Orbis’ nGen platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.
Industry
Biotech
Status
Current
Location
Denmark
From our earliest days, Forbion backed Orbis and its bold idea: oral macrocycles with the potency of biologics. That idea has become a powerful AI-driven platform, an emerging pipeline, and a multi-target collaboration with Novo Nordisk. I'm grateful for Forbion's partnership as we turn that foundation into medicines that matter for patients."Joanne Smith-Farrell, PhD
CEO
